Drug Profile

CYP 006TK

Alternative Names: Cymerus mesenchymal stem cells; CYP-006TK

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cynata Therapeutics
Class Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Diabetic foot ulcer

Most Recent Events

28 Feb 2025 No recent reports of development identified for phase-I development in Diabetic-foot-ulcer in Australia (Topical)
04 Dec 2024 Cynata Therapeutics completes a phase-I clinical trial in Diabetic foot ulcer in Australia (Topical) (NCT05165628)
04 Dec 2024 CYP 006TK is available for licensing as of 04 Dec 2024. http://www.cynata.com

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com